The Centers for Medicare & Medicaid Services Friday issued a national decision to cover diagnostic laboratory tests using next generation sequencing for certain Medicare patients with advanced cancer. “These tests can help doctors consult with patients about more targeted care or enrollment in a clinical trial,” said CMS Chief Medical Officer Kate Goodrich, M.D. “The expanded coverage in this final [national coverage determination] now includes additional tests for relapsed, refractory and earlier stage III cancers to aid in the treatment of these cancer patients.”

Related News Articles

Headline
The House today voted 220-207 to pass the Inflation Reduction Act (H.R. 5376), sending it to President Biden for his signature. Passed by the Senate Sunday,…
Headline
The first Centers for Medicare & Medicaid Services model to screen patients for health-related social needs and refer them to needed services ended in…
Headline
The Senate this weekend is expected to take up the Inflation Reduction Act (H.R. 5376), the latest version of the Build Back Better Act, a roughly $700 billion…
Headline
The Department of Justice today filed a lawsuit challenging an Idaho law restricting abortion. The complaint seeks a declaratory judgment that the law…
Headline
The Centers for Medicare & Medicaid Services today issued a final rule that updates the inpatient prospective payment system rates by 2.6% in FY 2023…
Headline
The Centers for Medicare & Medicaid Services today issued a final rule for the long-term care hospital prospective payment system for fiscal year 2023,…